A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Study sponsor: Xenon Pharmaceuticals Inc. · XENE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-04Estimated
Enrollment · participants160Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.